Galectin Therapeutics (GALT) Equity Average (2011 - 2026)

Galectin Therapeutics' Equity Average history runs 16 years deep, the most recent figure standing at -$129.9 million for Q1 2026.

• In Q1 2026, Equity Average fell 18.79% year-over-year to -$129.9 million; the TTM figure through Mar 2026 stood at -$129.9 million (down 18.79% YoY), while the FY2025 annual figure was -$116.4 million, down 39.55% from the prior year.
• Equity Average was -$129.9 million for Q1 2026 at Galectin Therapeutics, down from -$126.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of -$3.5 million in Q1 2022 to a low of -$129.9 million in Q1 2026.
• Historically, Equity Average has averaged -$69.0 million across 5 years, with a median of -$57.3 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Equity Average sank 1014.71% in 2023, then fell 18.79% in 2026.
• A 5-year view of Equity Average shows it stood at -$29.0 million in 2022, then plunged by 97.6% to -$57.3 million in 2023, then plunged by 73.71% to -$99.5 million in 2024, then declined by 27.25% to -$126.6 million in 2025, then fell by 2.63% to -$129.9 million in 2026.
• The last three Equity Average figures came in at -$129.9 million (Q1 2026), -$126.6 million (Q4 2025), and -$122.1 million (Q3 2025), per Business Quant data.